SKS Development

SKS Development is a clinical-stage biopharmaceutical company focused on developing innovative ophthalmic treatments using proprietary drug delivery technologies. The company specializes in creating advanced formulations, such as nano-emulsions, to enhance the bioavailability and therapeutic profile of drugs for ocular diseases. Its lead candidate, SKS-722, is a novel formulation of cyclosporine being evaluated for the treatment of dry eye disease. Other clinical programs include SKS-01 for allergic conjunctivitis and SKS-11 for glaucoma, both of which utilize the company's delivery platform to improve patient outcomes. By optimizing the delivery of active pharmaceutical ingredients, SKS Development aims to address unmet needs in eye care through superior solubility and reduced irritation. The company's technology is based on the research of Professor Shlomo Magdassi from the Hebrew University of Jerusalem.